Wall Street analysts changed outlook on top names. For full view of analyst rating changes, see analyst ratings page. See how other analysts view these stocks.
Google (GOOGL) and SpaceX are reportedly in talks for orbital data centers, lending credence to space-based computing ahead of a targeted $2T SpaceX IPO.
Law enforcement stalwart Axon keeps winning with its earnings reports, but the stock remains deeply depressed from highs as AI becomes a growth driver.
ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-expected financial results and guidance. Peltz may take Wendy's private.
Amazon is expanding its 30-minute "Amazon Now" delivery service and rolling out Prime Video's short-form "Clips" feature as it pushes deeper into instant commerce and mobile engagement.
Millicom International Cellular (NASDAQ:TIGO) reported what management described as a solid start to 2026, with first-quarter revenue and cash flow boosted by recent acquisitions and continued growth in its core mobile business.
On the company’s earnings call, CEO Marcelo Benitez said Millicom deli
Veritone (NASDAQ:VERI) reported lower first-quarter revenue but reaffirmed its full-year 2026 outlook, citing growing demand for its AI training data services, public sector software and recently expanded relationships with major technology companies.
On the company’s first-quarter earnings call, P
Wise (LON:WISE) executives used an investor presentation in New York to outline the company’s growth strategy following its Nasdaq listing, emphasizing its cross-border payments infrastructure, expanding product suite and medium-term financial targets.
Founder and CEO Kristo Käärmann said Wise was
Silvercrest Asset Management Group (NASDAQ:SAMG) reported flat first-quarter revenue and sharply lower earnings as the firm continued what management described as the most significant investment program in its history, aimed at expanding its global distribution, investment capabilities and successio
Satellogic (NASDAQ:SATL) reported a sharp increase in first-quarter revenue and said it generated positive net cash from operating activities for the first time in its public history, as management pointed to growing demand from sovereign defense, intelligence and commercial customers.
Founder and
SAB Biotherapeutics (NASDAQ:SABS) said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinical-stage biopharmaceutical company reported a wider first-quarter loss alongside higher research and development spending.
Chief Executive Officer Sa
Nayax (NASDAQ:NYAX) reported a strong start to 2026, with first-quarter revenue rising 32% year over year to approximately $107 million as the payments and commerce platform expanded its installed device base and customer count.
Co-Founder and Chief Executive Officer Yair Nechmad said the quarter r
